

ANTIFUNGAL

NAPS

National Antimicrobial
Prescribing Survey



Antifungal NAPS targeted audit 2026

- We invite all hospitals to participate in a **targeted audit** of **echinocandin** prescribing
- **Deep dive** into the prescribing of echinocandins in your hospital
- **Benchmark** quality and outcome metrics to similar facilities

WHY assess echinocandin prescribing?

- Widely used **broad-spectrum** antifungals
- Commonly **initiated early** in care, with variable rates of timely **review and step-down**
- Prolonged or unnecessary use increases **cost** and selection pressure and contributes to **antifungal resistance**

HOW is Antifungal NAPS different?

- Deep dive audit to **assess each phase** of echinocandin prescribing (prophylaxis, empiric & directed therapy)
- Assess prescribing according to **risk of infection**
- **Quality & outcome metrics** specific for antifungal prescribing and invasive fungal infection





Participate in the 2026 Antifungal NAPS targeted audit

Who can participate?

- All Australian hospitals are encouraged to participate

What is being audited?

- All patients newly initiated on an echinocandin (anidulafungin, caspofungin, micafungin) in any setting of your hospital

What time period should be audited?

- 1st January to 31st March 2026
- This audit is conducted retrospectively

How many prescriptions should be audited?

- All patients initiated on an echinocandin during the audit period
- If there are > 50 patients in your facility prescribed an echinocandin, you may choose to restrict the audit to the first 50 patients

Submission deadline to participate in benchmarking

- 31st December 2026

NAPS website



Log in to an existing account or Register for a new account
Select **Hospital NAPS** → **Resources tab**

★ View training **videos & worked case examples**

★ Complete **eLearning** module

★ Download **User Guide & Data Collection Form**

Contact support@naps.org.au to find out more